China’s BeiGene raises $175m from follow-on
Nasdaq-listed Chinese biopharmaceutical firm BeiGene has bagged $175m from a follow-on public offering of American Depositary Shares (ADSs).
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts